Phase III Study of ASP2151 in Patients with Recurrent Genital Herpes

A Phase III, Placebo-controlled, Randomized, Double-blind, Multicenter, Parallel-group comparative study to Evaluate the Efficacy and Safety of Patient Initiated Therapy of ASP2151 in Patients with Recurrent Genital Herpes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224871

Enrollment

176

Registered

2019-09-13

Start date

2019-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Genital Herpes

Interventions

investigational material(s) Generic name etc : Amenamevir INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : Patients wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recurrent Genital Herpes patients

Exclusion criteria

Exclusion criteria: (1)Patients diagnosed with immunodeficiency or immunocompromised function (such as patients with congenital immunodeficiency, AIDS patients, patients with HIV infection) (2)Patients with any disorders that should not be enrolled in the sutdy such as; -severe cardiac disorders -severe hepatic disorders -severe pulmonary disorders -severe blood disorders (3)Pregnant women, women who may be pregnant, lactating women or women who wish to become pregnant or women who are unwilling to use a suitable method of contraception as directed by the principal investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
efficacy Time to healing of all genital herpes lesions	—

Secondary

Measure	Time frame
efficacy Time to complete crusting of all genital herpes lesions	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026